Janus Kinase Inhibitors

Janus Kinase Inhibitor

Arthritis, Rheumatoid

<section class="Section" data-sectioncode="34089-3"><a name="section-9"></a><h1>11 DESCRIPTION</h1>RINVOQ and RINVOQ LQ are formulated with upadacitinib, a JAK inhibitor. Upadacitinib has the following chemical name: (3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide hydrate (2:1). The strength of upadacitinib is based on anhydrous upadacitinib. The solubility of upadacitinib in water is 38 to less than 0.2 mg/mL across a pH range of 2 to 9 at 37 oC. Upadacitinib has a molecular weight of 389.38 g/mol and a molecular formula of C17H19F3N6O • ½ H2O. The chemical structure of upadacitinib is: <img alt="upadacitinib-chem-structure" src="rinvoq-01.jpg"/>RINVOQ 15 mg extended-release tablets for oral administration are purple, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a15’ on one side. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, ferrosoferric oxide, hypromellose, iron oxide red, magnesium stearate, mannitol, microcrystalline cellulose, polyvinyl alcohol, polyethylene glycol, talc, tartaric acid and titanium dioxide. RINVOQ 30 mg extended-release tablets for oral administration are red, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a30’ on one side. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, hypromellose, iron oxide red, magnesium stearate, mannitol, microcrystalline cellulose, polyvinyl alcohol, polyethylene glycol, talc, tartaric acid and titanium dioxide. RINVOQ 45 mg extended-release tablets for oral administration are yellow to mottled yellow, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a45’ on one side. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, hypromellose, iron oxide yellow, iron oxide red, magnesium stearate, mannitol, microcrystalline cellulose, polyvinyl alcohol, polyethylene glycol, talc, tartaric acid and titanium dioxide.RINVOQ LQ oral solution for oral administration is a 1 mg/mL clear, colorless to light yellow solution. Each 1 mL RINVOQ LQ contains 1 mg of upadacitinib as free base (equivalent to 1.02 mg upadacitinib hemihydrate) and the following inactive ingredients: citric acid anhydrous, purified water, sodium benzoate, sodium citrate dihydrate, and sucralose. </section>

Rinvoq

upadacitinib

24 HR upadacitinib 15 MG Extended Release Oral Tablet

24 HR upadacitinib 15 MG Extended Release Oral Tablet [Rinvoq]

24 HR upadacitinib 30 MG Extended Release Oral Tablet

24 HR upadacitinib 30 MG Extended Release Oral Tablet [Rinvoq]

24 HR upadacitinib 45 MG Extended Release Oral Tablet

24 HR upadacitinib 45 MG Extended Release Oral Tablet [Rinvoq]

upadacitinib 1 MG/ML Oral Solution

upadacitinib 1 MG/ML Oral Solution [Rinvoq]

CarelonRx Specialty Pharmacy

Actemra

Afinitor

Alecensa

Alunbrig

Aranesp

Avastin

Belodaq

Besponsa

Blincyto

Bosulif

Cabometyx

Cosentyx

Cotellic

Daurismo

Enbrel

Erivedge

Erleada

Farydak

Folotyn

Halavan

Herceptin

Ibrance

Idhifa

Imfinzi

Inlyta

Inrebic

Iressa

Istodax

Ixempra

Jakafi

Kadcyla

Keytruda

Khapzory

Kyprolis

Lonsurf

Lorbrena

Lynparza

Nplate

Mekinist

Nexavar

Nubeqa

Odomzo

Olumiant

Oncaspar

Opdivo

Perjeta

Polivy

Portrazza

Rituxan

Rozlyrek

Rubraca

Stelara

Stivarga

Sutent

Tagrisso

Tafinlar

Talzenna

Tarceva

Targretin

Tasigna

Treanda

Tykerb

Vidaza

Vitrakvi

Vizimpro

Xalkori

Xtandi

Yervoy

Yondelis

Yonsa

Zaltrap

Zelboraf

Zydelig

Zykadia

Rinvoq | CarelonRx Specialty Pharmacy

Which health plans does CarelonRx Specialty Pharmacy have contracts with?

Does CarelonRx Specialty Pharmacy work closely with Rinvoq and AbbVie Inc.?

Does CarelonRx Specialty Pharmacy offer services for Rinvoq patients?

What conditions does CarelonRx Specialty Pharmacy support?

How does CarelonRx Specialty Pharmacy help with insurance?